Evidence map›Paper›PMID 32588044›Full record

ArticleJournal of Crohn's & colitis2021

Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn's Disease Patients: A Case Report and Review of the Literature.

Pepijn W A Thomas, Gerben Ferwerda, Rachel L West, Frank Hoentjen

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Pepijn W A ThomasDepartment of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Gerben FerwerdaSection of Paediatric Infectious Diseases, Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Rachel L WestDepartment of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
Frank HoentjenDepartment of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Radboud University Nijmegen · NLSint Franciscus Gasthuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, ustekinumab has been approved for the treatment of Crohn's disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present details of three patients with therapy-refractory Crohn's disease who experienced an immediate infusion reaction to intravenous administration of ustekinumab. In two of these patients a subsequent reaction to subcutaneous injections occurred. Clinical features and pathophysiology are discussed.

Indexed as

Drug HypersensitivityDyspneaUstekinumabAdrenal Cortex HormonesAdultAnti-Inflammatory AgentsCrohn DiseaseDrug Administration RoutesFemaleHistamine AntagonistsHumansInjection Site ReactionMiddle AgedRemission InductionTreatment OutcomeWithholding TreatmentAdrenal Cortex HormonesAnti-Inflammatory AgentsHistamine AntagonistsUstekinumabCrohn’s diseaseinfusion reactionUstekinumab

Identifiers

PMID32588044
PMCPMC7805788
OpenAlexW3037278777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.